Cover Image

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting children. Although therapeutic strategies have improved, T-cell acute lymphoblastic leukemia (T-ALL) relapse is associated with chemoresistance and a poor prognosis. One strategy to overcome this obstacle is the applic...

Full description

Saved in:
Bibliographic Details
Main Authors: Müller, Kristina (Author) , Vogiatzi, Fotini (Author) , Winterberg, Dorothee (Author) , Rösner, Thies (Author) , Lenk, Lennart (Author) , Bastian, Lorenz (Author) , Gehlert, Carina L. (Author) , Autenrieb, Marie-Pauline (Author) , Brüggemann, Monika (Author) , Cario, Gunnar (Author) , Schrappe, Martin (Author) , Kulozik, Andreas (Author) , Eckert, Cornelia (Author) , Bergmann, Anke Katharina (Author) , Bornhauser, Beat (Author) , Bourquin, Jean-Pierre (Author) , Valerius, Thomas (Author) , Peipp, Matthias (Author) , Kellner, Christian (Author) , Schewe, Denis Martin (Author)
Format: Article (Journal)
Language:English
Published: 7 July 2022
In: Blood
Year: 2022, Volume: 140, Issue: 1, Pages: 45-57
ISSN:1528-0020
DOI:10.1182/blood.2021014485
Online Access:Resolving-System, lizenzpflichtig: http://dx.doi.org/10.1182/blood.2021014485
Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2021014485
Get full text
Author Notes:Kristina Müller, Fotini Vogiatzi, Dorothee Winterberg, Thies Rösner, Lennart Lenk, Lorenz Bastian, Carina L. Gehlert, Marie-Pauline Autenrieb, Monika Brüggemann, Gunnar Cario, Martin Schrappe, Andreas E. Kulozik, Cornelia Eckert, Anke K. Bergmann, Beat Bornhauser, Jean-Pierre Bourquin, Thomas Valerius, Matthias Peipp, Christian Kellner, and Denis M. Schewe
Description
Summary:Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting children. Although therapeutic strategies have improved, T-cell acute lymphoblastic leukemia (T-ALL) relapse is associated with chemoresistance and a poor prognosis. One strategy to overcome this obstacle is the application of monoclonal antibodies. Here, we show that leukemic cells from patients with T-ALL express surface CD38 and CD47, both attractive targets for antibody therapy. We therefore investigated the commercially available CD38 antibody daratumumab (Dara) in combination with a proprietary modified CD47 antibody (Hu5F9-IgG2σ) in vitro and in vivo. Compared with single treatments, this combination significantly increased in vitro antibody-dependent cellular phagocytosis in T-ALL cell lines as well as in random de novo and relapsed/refractory T-ALL patient-derived xenograft (PDX) samples. Similarly, enhanced antibody-dependent cellular phagocytosis was observed when combining Dara with pharmacologic inhibition of CD47 interactions using a glutaminyl cyclase inhibitor. Phase 2-like preclinical in vivo trials using T-ALL PDX samples in experimental minimal residual disease-like (MRD-like) and overt leukemia models revealed a high antileukemic efficacy of CD47 blockade alone. However, T-ALL xenograft mice subjected to chemotherapy first (postchemotherapy MRD) and subsequently cotreated with Dara and Hu5F9-IgG2σ displayed significantly reduced bone marrow infiltration compared with single treatments. In relapsed and highly refractory T-ALL PDX combined treatment with Dara and Hu5F9-IgG2σ was required to substantially prolong survival compared with single treatments. These findings suggest that combining CD47 blockade with Dara is a promising therapy for T-ALL, especially for relapsed/refractory disease harboring a dismal prognosis in patients.
Item Description:Gesehen am 25.09.2022
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.2021014485

Similar Items